Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyBCBS Louisiana Allergen Testing Coverage Update | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Modifiedblue cross blue shield - louisianaPolicy AHS - G2031 - Allergen Testing

    Allergen Testing

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy AHS - G2031 - Allergen Testing alerts

    Get alerted when Policy AHS - G2031 - Allergen Testing changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage criteria and limitations for in‑vitro and skin‑based allergen testing, including specific IgE, total IgE, basophil activation testing, proprietary panels, and other ancillary tests for Blue Cross Blue Shield of Louisiana members.

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyAllergen Testing
    Policy CodePolicy AHS - G2031 - Allergen Testing
    Change TypeCoverage criteria added/revisedCPT update
    Effective DateSep 15, 2026
    Last ReviewSep 15, 2026
    Next Review DateMar 18, 2026
    Key ActionDo not perform specific IgE in‑vitro testing on the same day as skin prick testing; such same‑day testing will be denied.
    SourceLink
    POLICY UPDATE CHANGES

    New CC4: 'When performed on the same day as skin prick testing, specific IgE in-vitro allergy testing DOES NOT MEET COVERAGE CRITERIA'.

    Added CPT code 95004.

    Removed CC1 (clinical guidance only) and associated Note 1 defining contraindications for skin testing.

    Client requested variance: Addition of CC2c for individuals with chronic rhinosinusitis with nasal polyps being considered for Xolair therapy.

    CC4 added previously stating annual re-testing for same food allergens meets coverage criteria in children/adolescents was edited and CC5 edited for clarity.

    up to 20allergen-specific IgE tests covered per year
    MEETS COVERAGEtotal serum IgE
    DOES NOT MEETsame-day in-vitro with skin prick
    95004CPT code added
    DOES NOT MEETALCAT
    CPT listprocedure codes enumerated

    Coverage Criteria and Medical Necessity

    Covered: Specific IgE in-vitro testing (limited panel)

    Covered when ALL of the following are met

    Covered specific IgE testing: Specific IgE in‑vitro allergy testing up to 20 allergen‑specific antibodies per year when allergens are chosen based on the individual's history, physical examination, and environment.up to 20 per year

    Per policy: selection of allergens must be guided by clinical history/exam and environment.

    Covered: Total serum IgE

    Covered in any of the following situations (OR logic across listed indications)

    Total serum IgE coverage criteria: Total serum IgE testing meets coverage criteria for individuals with: (a) moderate to severe asthma; (b) signs or symptoms of allergic bronchopulmonary aspergillosis (ABPA); (c) chronic rhinosinusitis with nasal polyps when being considered for omalizumab (Xolair) therapy.

    Listed as discrete indications in policy.

    Covered: Monitoring food allergy resolution in children/adolescents

    Covered when ALL of the following are met

    Annual re-testing for food allergen resolution: Annual re‑testing for the same food allergen(s) meets coverage criteria for children and adolescents with an initial positive food allergen result(s) to monitor for resolution.annual

    Applies only to children and adolescents per policy; frequency stated as yearly re‑evaluation in guideline context.

    Not Medically Necessary / Not Covered

    Explicitly not covered tests: The following do NOT meet coverage criteria: (1) specific IgE in‑vitro allergy testing performed on the same day as skin prick testing; (2) routine re‑testing for the same allergens in the absence of a new clinical presentation (except annual pediatric food re‑testing as specified); (3) the Antigen Leukocyte Antibody Test (ALCAT); (4) basophil activation flow cytometry testing and in‑vitro testing of IgG, IgA, IgM, and/or IgD for allergy; (5) in‑vitro bead‑based epitope assays (e.g., VeriMAP Peanut Dx); and (6) qualitative multi‑allergen screens that do not identify a specific allergen.

    Listed exclusions due to insufficient evidence or redundancy with skin testing.

    Guideline-supported indications and testing pathways

    Tests and indications supported by professional guidelines:

    General indication for allergy testing: Symptoms such as itchy eyes/nose/throat, nasal congestion, sneezing, watery eyes, cough/wheezing, eczema, severe insect sting reactions, anaphylaxis, and suspected food reactions warrant allergy testing; skin prick testing (SPT) is preferred when feasible and serum sIgE is an alternative when skin testing is unsafe or not useful.

    Based on AAAAI/ACAAI practice parameters.

    When to prefer serum sIgE over skin testing: Prefer in‑vitro specific IgE immunoassays instead of skin testing for patients with widespread skin disease, those receiving skin‑test suppressive therapy, uncooperative patients, or when history suggests high anaphylaxis risk from skin testing.

    AAAI/ACAAI guidance.

    Food allergy testing approach: For suspected peanut allergy with high pretest probability, perform SPT or sIgE; consider Ara h 2 component testing when using a single diagnostic test; routine additional component testing alongside SPT or sIgE is not routinely recommended.

    AAAI 2020 practice parameter update.

    Covered when clinically indicated

    Testing is supported when clinical history and examination indicate probable IgE-mediated disease or suspected contact dermatitis requiring patch testing; specialist-level testing may be appropriate in select scenarios.

    Indications for SPT or serum sIgE: Indications include asthma, rhinitis/rhinosinusitis, conjunctivitis, suspected food allergy (anaphylaxis or temporally correlated urticaria/eczema), suspected drug allergy, hymenoptera venom allergy, suspected occupational allergy, and select cases of chronic urticaria or eosinophilic disorders where IgE sensitization is relevant.

    Supported by WAO, NIAID, International Consensus.

    Indications for patch testing: When allergic contact dermatitis is suspected in characteristic locations (eg, face/periorbital, lips/perioral, scalp/neck, hands, axilla, anogenital region), perform patch testing to relevant product components.

    JTFPP summary statements.

    Specialist or adjunct testing: Component‑resolved diagnostics, nasal sIgE, basophil activation tests, nasal provocation, and other advanced assays may be used selectively for polysensitized patients, local allergic rhinitis, or when conventional tests are not possible or are conflicting.

    Coverage and clinical criteria (summary)

    Clinical guidance summarized from cited organizations:

    General approach: Begin allergy evaluation with an allergy‑focused clinical history and physical exam; select and interpret SPT or serum‑specific IgE testing based on that history, performed by clinicians with appropriate competencies.

    NASEM, NICE, AAFP, Royal College summaries.

    Food allergy diagnostic pathway: For suspected IgE‑mediated food allergy, offer SPT and/or blood specific IgE testing guided by history; consider diagnostic elimination diets and oral food challenge as the confirmatory test when indicated.

    NASEM and NICE recommendations.

    Specialized tests: Component‑resolved diagnostics and BAT may be useful in selected situations (eg, polysensitized patients or when conventional tests conflict) but are generally specialist/research tools pending wider standardization.

    EAACI, NASEM, EAACI Molecular Allergology guidance.

    Notable Coverage Criteria Updates

    Policy-level coverage criteria updates and notable rules from the review history:

    CC4: When performed on the same day as skin prick testing, specific IgE in‑vitro allergy testing DOES NOT MEET COVERAGE CRITERIA.

    New explicit exclusion added in review history.

    CC1 (revised): Specific IgE in‑vitro allergy testing MEETS COVERAGE CRITERIA in situations including: a) in lieu of skin testing for an initial allergy screen; b) when skin testing is contraindicated; (former CC2 reorganized into CC1).

    Former CC2 became CC1 focused on annual number/usage.

    CC2c (client variance): For individuals with chronic rhinosinusitis with nasal polyps being considered for omalizumab (Xolair) therapy, total serum IgE testing is addressed as a coverage condition per client variance.

    Client‑requested variance added in revision.

    Annual pediatric re‑testing:

    The policy explicitly identifies several nonstandard or qualitative multi‑allergen assays as not meeting coverage criteria due to insufficient evidence of clinical utility. Specifically, the document lists qualitative multi‑allergen screens that do not identify specific allergens, ALCAT (Antigen Leukocyte Antibody Test), and bead‑based epitope assays (for example, VeriMAP) among tests excluded from coverage. These proprietary or broad panel tests are noted for limited reproducibility, lack of correlation with clinical allergy, and insufficient published evidence to support routine clinical use.

    The policy states that IgG and IgG subclass antibody tests for food allergy are not clinically relevant and should not be performed. Guideline text cited in the policy indicates these tests are not validated, lack sufficient quality control, and their presence typically reflects prior exposure rather than hypersensitivity, making them unsuitable for diagnosing IgE‑mediated food allergy.

    Professional society guidance and the policy discourage routine use of broad specific IgG or indiscriminate IgE food panels. The document notes Choosing Wisely and AAAAI recommendations against performing unproven diagnostic tests or an indiscriminate battery of IgE tests, and emphasizes that specific testing should be guided by the patient’s clinical history and targeted to relevant allergens rather than routine panel screening.

    The policy identifies a range of unproven or commercially marketed diagnostic tests that do not meet coverage criteria. Examples called out include the ALCAT (leukocyte stimulation test), various laboratory‑developed multi‑analyte microarrays and panel tests, and other procedures described in the literature as unproven for routine clinical allergy diagnosis. The rationale cites limited reproducibility and insufficient peer‑reviewed evidence supporting clinical benefit.

    The policy makes clear that specific IgE in‑vitro allergy testing performed on the same day as skin prick testing DOES NOT MEET COVERAGE CRITERIA. Same‑day in‑vitro testing conducted in conjunction with percutaneous skin testing will be denied under this policy.

    Routine repeat testing for the same allergens in the absence of a new clinical presentation is not covered. The policy states that routine re‑testing for the same allergens DOES NOT MEET COVERAGE CRITERIA, with the exception noted elsewhere for annual re‑testing in children and adolescents to monitor food allergy resolution.

    The policy and guideline sources recommend against routine or indiscriminate battery testing. Ordering broad, non‑targeted panels without a supporting clinical history is discouraged and may lead to inappropriate diagnoses; testing should be limited to allergens selected on the basis of a focused history, exam, and likely exposures.

    Ordering specific IgG testing to food panels or broad, indiscriminate IgE screening without a clinical history indicating likely allergens is considered not medically necessary. Choosing Wisely and specialty guidance emphasize that IgG panels reflect exposure rather than allergy and can result in misdiagnosis and unnecessary interventions.

    The policy states that routine use of nonstandardized tests—including many commercial food sensitivity assays and other unvalidated procedures—is not supported. While some assays (for example, basophil activation tests) may have research or specialist roles, the policy identifies functional and proprietary assays without standardized methodology as not meeting coverage criteria for routine clinical diagnosis.

    Except for specified exceptions (such as annual pediatric re‑testing to monitor food allergy resolution), the policy reiterates that routine re‑testing for the same allergens DOES NOT MEET COVERAGE CRITERIA. Providers should document a new clinical presentation or other justifying indication before repeating tests for the same allergens.

    Procedure Codes and Proprietary Test Codes

    Applicable CPT/HCPCS Procedure CodesCPT
    82784Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each.
    82785Gammaglobulin (immunoglobulin); IgE.
    82787Gammaglobulin (immunoglobulin); immunoglobulin subclasses (eg, IgG1, 2, 3, or 4), each.
    83516Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method.
    86001Allergen specific IgG quantitative or semiquantitative, each allergen.
    86003Allergen specific IgE; quantitative or semiquantitative, crude allergen extract, each.
    86005Allergen specific IgE; quantitative or semiquantitative, crude allergen extract, each Allergen specific IgE; qualitative, multiallergen screen (eg, disk, sponge, card).
    86008Allergen specific IgE; quantitative or semiquantitative, recombinant or purified component, each.
    88184Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker.
    88185Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker.
    1–10 of 11
    1/2
    Proprietary tests referencedmixed
    ProprietaryVeriMAP™ Peanut Dx - Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA); blood, individual epitope results and probability of peanut allergy (AllerGenis Clinical Laboratory).
    ProprietaryVeriMAP™ Peanut Sensitivity - Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA); blood, report of minimum eliciting exposure for a clinical reaction (AllerGenis Clinical Laboratory).
    CPT Changes / AddedCPT
    95004Added CPT code (policy text indicates CPT 95004 was added)
    CPT Changes / RemovedCPT
    83520Removed (reference: policy notes indicate code 83520 was removed)

    Provider Requirements, Documentation, and Billing Guidance

    Prior Authorization

    Prior authorization — none specified

    No explicit prior authorization requirements are stated in this excerpt of the policy.

    Prior Authorization

    Prior authorization for broad/indiscriminate panels

    Broad or indiscriminate multi-allergen panels that are not clinically justified may require additional justification and could be subject to prior authorization per payer processes.

    • Policy emphasizes selecting allergens based on history, exam, age, environment, region, occupation, and activities.
    • Indiscriminate multi-allergen screens that do not identify specific allergens DO NOT MEET COVERAGE CRITERIA.
    Prior Authorization

    Obtain total serum IgE to support biologic dosing (e.g., Xolair)

    Background, Definitions, and Test Descriptions

    Allergic disease represents inappropriate immune responses, most commonly IgE‑mediated (Type I) hypersensitivity, or less commonly T cell‑mediated (Type IV) reactions. Accurate diagnosis requires identification of the suspected allergen, demonstration of specific IgE or other relevant immune markers, and correlation of test results with the clinical history. The policy highlights that skin prick testing (SPT) is rapid and widely used, whereas in‑vitro specific IgE testing is an alternative when skin testing is unsafe or impractical; testing choice and interpretation must be grounded in an allergy‑focused history and physical examination.

    inv-45: sIgE / specific IgE — Definition of allergen-specific IgE measured in serum
    DefinitionAllergen-specific immunoglobulin E (sIgE) measured in serum to detect sensitization to specific allergens.
    Clinical useDetects sensitization when skin testing is unavailable or unsafe (e.g., extensive dermatitis, inability to stop antihistamines); used as an alternative to SPT.
    Interpretation notePresence of sIgE indicates sensitization but does not by itself confirm clinical allergy; correlate results with history and exam.
    Coverage limit
    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyAllergen Testing
    Policy CodePolicy AHS - G2031 - Allergen Testing
    Change TypeCoverage criteria added/revisedCPT update
    Effective DateSep 15, 2026
    Last ReviewSep 15, 2026
    Next Review DateMar 18, 2026
    Key ActionDo not perform specific IgE in‑vitro testing on the same day as skin prick testing; such same‑day testing will be denied.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityProcedure Codes and Proprietary Test CodesProvider Requirements, Documentation, and Billing GuidanceBackground, Definitions, and Test Descriptions
    Use of BAT and advanced tests: Basophil activation test (BAT) and functional assays may be useful when SPT and sIgE results are equivocal and can reduce need for oral food challenges in selected cases, but are generally specialist/research tools pending standardization.

    Guideline and evidence summaries (Santos et al., EAACI, NASEM).

    Patch testing guidance: Patch testing is the gold standard to confirm allergic contact dermatitis and should be performed when allergic contact dermatitis is suspected based on clinical presentation.

    JTFPP recommendations.

    International Consensus, WAO, EAACI guidance.

    In vivo and ancillary tests:
    Nasal provocation, nasal cytology, rhinomanometry and related adjunctive tests can aid in selected cases (eg, local or occupational rhinitis) but should not replace history and standard SPT/sIgE testing.

    International Consensus Statement and NICE.

    Annual re‑testing for the same food allergens in children and adolescents with prior positive results MEETS COVERAGE CRITERIA to monitor for allergy resolution.
    annual

    Referenced as edited CC in review history.

    Measure serum total IgE prior to initiation of certain biologic therapies (example: omalizumab/Xolair) because dosing is determined by pre-treatment total IgE level and body weight.

    • Determine dose and dosing frequency by serum total IgE level (IU/mL) measured before the start of treatment per Xolair prescribing information.
    • Documented IgE level should be available when seeking authorization for such therapy.
    Billing Rule

    Procedure codes referenced for allergen testing

    Use the policy’s listed CPT/HCPCS codes when ordering or billing for allergen testing; these include codes for allergen-specific IgE, immunoassays, flow cytometry markers, and percutaneous skin tests.

    • Relevant codes: 82784, 82785, 82787, 83516, 86001, 86003, 86005, 86008, 88184, 88185, 95004.
    • Procedure codes in the policy may be subject to payer prior authorization and should be used as referenced.
    Billing Rule

    CPT update — 95004 added

    CPT code 95004 (percutaneous tests with interpretation) was added to the policy; providers should bill using the appropriate CPT codes listed in the policy.

    • 95004: Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report; specify number of tests.
    Step Therapy

    Step therapy — none specified

    No step therapy requirements are described in this portion of the document.

    Step Therapy

    Two‑step testing approach for peanut — SPT/Ara h 2 then BAT

    For suspected peanut allergy, use a staged diagnostic approach: perform skin prick testing (SPT) or component testing (e.g., Ara h 2) first and reserve basophil activation testing (BAT) for equivocal cases or specialist settings.

    • BAT may be performed only after equivocal SPT or Ara h 2 sIgE and can markedly reduce the need for oral food challenges.
    Note

    Provider actions — not specified

    Not specified in this excerpt.

    Step Therapy

    Step therapy — not described

    No step therapy requirements are specified in this document excerpt.

    Documentation Required

    Limit testing to allergens justified by history/exam/environment

    Testing is covered only for allergens chosen based on the individual’s history, physical examination, and environment; document the clinical rationale linking selected allergens to the history and exam.

    • Specific IgE in‑vitro testing coverage limited to up to 20 allergen-specific antibodies per year when selection is based on history, exam, and environment.
    • Select allergens considering patient age, region, occupation, activities, and prevalence in ambient air.
    Documentation Required

    Document clinical rationale and test selection

    Document clinical rationale for test selection: record how history, physical exam, age, environment, region, occupation, and activities informed the allergens and modality chosen (SPT vs serum sIgE).

    • When serum sIgE is used instead of skin testing, document the reason (e.g., widespread skin disease, skin‑test suppressive therapy, uncooperative patient, high anaphylaxis risk).
    • For food allergy follow-up in children, document rationale for annual re-testing to monitor for resolution when applicable.
    Documentation Required

    Document detailed history, exam, medication review, and clinician competency

    Record a detailed allergy-focused history, focused physical examination, and medication review before testing; document that testing and interpretation were performed by clinicians with appropriate competencies and that facility readiness (eg, anaphylaxis management) is available for skin testing.

    • NICE: Do not carry out allergy testing without first taking an allergy-focused clinical history and interpret results in that context.
    • JTFPP: Complete a detailed history and physical exam for rhinitis and review medications prior to testing.
    Documentation Required

    Required documentation and clinician competencies

    Ensure allergy-focused clinical history is documented prior to testing and confirm that the ordering/interpreting clinician has competency in test selection and interpretation.

    • Royal College: Only test ASIgE for food when answers to key clinical questions confirm an IgE-mediated mechanism and limit testing to relevant trigger foods.
    • Document that testing will affect management (eg, avoidance, immunotherapy referral) as appropriate.
    Documentation Required

    Document indications consistent with updated CCs and CPT updates

    Align documentation with updated coverage criteria and CPT changes: when using specific IgE in lieu of skin testing or for pediatric food re-testing, document the indication consistent with the revised CCs.

    • New CC4 prohibits same‑day specific IgE in‑vitro testing with skin prick testing — document testing dates to show compliance.
    • 95004 was added to the policy; ensure coding in documentation matches the policy codes.
    Denial Risk

    Denial risk — same‑day in‑vitro sIgE with skin prick testing

    Specific IgE in‑vitro testing performed on the same day as skin prick testing is excluded from coverage and will be denied.

    • Ensure serum testing is not performed the same day as SPT; document dates/times of tests if needed for audit or prior authorization.
    Denial Risk

    Denial risk — routine re‑testing without new clinical presentation

    Routine re-testing for the same allergens without a new clinical presentation does not meet coverage and will be denied, except for annual food allergen re‑testing in children/adolescents to monitor for resolution.

    • If repeating tests, document new clinical signs/symptoms or explicit pediatric monitoring rationale to support coverage.
    • Annual re-testing for food allergen resolution is covered only for children and adolescents with prior positive results.
    Denial Risk

    Denial risk — unproven or indiscriminate testing (IgG, ALCAT, broad panels)

    Ordering indiscriminate battery testing or unproven tests (e.g., IgG food panels, ALCAT, bead‑based epitope assays) is discouraged by professional societies and may be denied as not meeting coverage criteria.

    • ALCAT and bead‑based epitope assays (eg, VeriMAP) DO NOT MEET COVERAGE CRITERIA.
    • IgG and IgG subclass antibody tests for food allergy lack validation and should not be performed.
    Denial Risk

    Denial risk — testing for not‑routinely‑indicated indications

    Do not order skin prick testing or serum testing for indications explicitly listed as not routinely indicated (eg, specific IgG panels for food, suspected food intolerance without allergic features, chronic urticaria without allergic history, or screening asymptomatic individuals) because such orders may be denied.

    • WOA and other guidelines list multiple not‑routinely‑indicated scenarios where testing is not supported.
    • Document the presence of allergic features if testing is pursued in borderline cases.
    Denial Risk

    Denial risk — lack of allergy‑focused history and contextual interpretation

    Always obtain and document an allergy‑focused clinical history prior to testing and interpret results in that context; failure to do so may trigger denial risk.

    • NICE: Do not carry out allergy testing without first taking an allergy‑focused clinical history and interpret test results in that context.
    • JTFPP: Complete a detailed history, exam, and medication review to support indications for testing.
    Denial Risk

    Same‑day testing denial risk — separate testing days required

    Perform in‑vitro specific IgE testing and skin prick testing on separate days; same‑day testing will trigger non‑coverage.

    • Document the dates of SPT and in‑vitro testing to demonstrate they were not performed the same day.
    • If both modalities are clinically necessary, schedule them on different days and record the clinical justification.
    Policy permits in‑vitro sIgE testing up to 20 allergen-specific antibodies per year when allergens are chosen based on history, exam, and environment.
    inv-46: tIgE / total IgE — Definition and clinical contexts where total IgE is useful
    DefinitionTotal serum immunoglobulin E (tIgE): the aggregate concentration of IgE in serum.
    Clinical contextsHas modest value as a screening test for allergic disease; useful in specific situations such as moderate‑to‑severe asthma, evaluation for allergic bronchopulmonary aspergillosis (ABPA), and when determining dosing for omalizumab (Xolair) in select patients.
    LimitationsNot recommended as a routine diagnostic screen for food allergy or to predict allergic disease risk; interpret within clinical context.
    inv-47: Basophil activation test (BAT) — Definition and limitations
    DefinitionBasophil activation test (BAT) is an ex vivo, flow cytometry–based assay that measures basophil activation markers after allergen stimulation.
    Current limitationsClinical use is limited by lack of standardized methodology, variable instrumentation, and need for further validation and quality assurance; generally considered a specialist or research tool pending standardization.
    Research roleShows promising specificity and potential to reduce need for oral food challenges in selected cases; used in research and specialized laboratories.
    inv-48: ALCAT / proprietary panels / bead-based epitope assays — Definitions and analytic concerns
    DefinitionALCAT and similar proprietary multi‑analyte panels or bead‑based epitope assays (e.g., VeriMAP) are laboratory‑developed tests that measure leukocyte reactions or epitope‑specific antibody binding across many analytes.
    Analytic concernsPublished evidence shows reproducibility and clinical correlation are limited for some proprietary assays (e.g., ALCAT); additional peer‑reviewed data are needed to establish analytical and clinical validity for emerging bead‑based epitope tests.
    Policy stanceThese multi‑analyte qualitative screens and certain proprietary assays are considered not to meet coverage criteria due to insufficient validation and unclear clinical utility.
    inv-49: Basophil activation test (BAT) — In-vitro assay measuring basophil markers after stimulation; diagnostic utility description
    Assay descriptionAn in‑vitro assay measuring basophil surface activation markers (for example CD63, CD203c) after allergen stimulation using flow cytometry.
    Diagnostic utilityBAT has demonstrated high specificity and comparable sensitivity versus SPT and sIgE in selected food allergy studies and can help predict reaction thresholds and severity in research cohorts.
    Practical noteBecause of variability between systems and limited standardization, BAT is mainly used in specialized centers or research settings rather than routine clinical practice.
    inv-50: Component testing (e.g., Ara h 2) — Definition of component-resolved diagnostics and benefit in selected scenarios
    DefinitionComponent testing (component‑resolved diagnostics) measures sIgE to specific allergen molecules (eg, Ara h 2 for peanut) rather than whole‑extract allergens.
    Clinical benefitCan improve diagnostic accuracy for certain allergens—Ara h 2 has superior diagnostic accuracy for peanut when a single test is used—helping to distinguish true sensitization from clinically irrelevant sensitization.
    Use recommendationsRecommended selectively (eg, polysensitized patients or when a single diagnostic test is desired); routine use in addition to SPT or sIgE is not advised by guidelines.
    inv-51: SPT (skin prick testing) — Definition and role in diagnosis
    DefinitionSkin prick testing (SPT) is an in‑vivo procedure that introduces standardized allergen extracts into the epidermis to detect IgE‑mediated sensitization via a wheal‑and‑flare reaction on the skin.
    Role in diagnosisSPT is the preferred, rapid, cost‑effective method for detecting IgE‑mediated sensitization and is recommended as first‑line testing when appropriate; results must be interpreted with clinical history by a trained clinician.
    When to use serum insteadUse serum sIgE instead of SPT when skin testing is unsafe or impractical (eg, extensive dermatitis, ongoing antihistamine therapy, or high anaphylaxis risk).
    inv-52: Component-resolved diagnostics (CRD) — Definition and selective use
    DefinitionComponent‑resolved diagnostics (CRD) are molecular‑based tests that assess IgE against specific allergenic molecules rather than whole extracts.
    Selective useCRD is an option for specialists and is useful in polysensitized patients or when molecular information can change diagnosis or management decisions.
    Guideline guidanceGuidelines recommend CRD in select scenarios but advise against routine component testing in addition to SPT or sIgE for most patients.
    inv-53: Patch testing (PT) — Definition and recommended use for contact dermatitis
    DefinitionPatch testing (PT) is epicutaneous application of allergens to the skin (occlusive or other methods) to identify contact allergens causing allergic contact dermatitis (ACD).
    Recommended usePatch testing is the gold standard to confirm allergic contact dermatitis and should be performed when ACD is suspected based on exposure‑related dermatitis presentations.
    Technique noteVariants include occlusive patch testing, open, provocative, photopatch, repeated insult, and atopy patch tests for special situations.
    inv-54: Molecular/allergen component testing — Option for assessment in polysensitized patients and by specialists
    DefinitionMolecular/allergen component testing evaluates sIgE to defined allergenic molecules to refine diagnosis beyond whole‑extract testing.
    Clinical applicationUseful for assessment of polysensitized patients, clarifying cross‑reactivity, or when specialist input will guide management decisions.
    Access and expertiseTypically used by specialists; interpretation requires molecular allergology knowledge and should be integrated with clinical history and other test results.
    inv-55: Basophil Activation Test (BAT) — Promising test recommended for research or specialized use pending standardization
    SummaryThe Basophil Activation Test (BAT) is a laboratory assay with promising data for confirming food, venom, and respiratory allergies but currently lacks full standardization for routine clinical use.
    RecommendationBAT is recommended for research or specialized clinical use pending standardized methods, quality assurance, and further clinical validation.
    Potential impactIn selected cases (eg, equivocal SPT/sIgE), BAT may reduce the need for oral food challenges and improve diagnostic specificity in specialized centers.
    inv-56: Specific IgE in-vitro allergy testing — Definition as alternative to skin testing and clinical scenarios for use
    DefinitionSpecific IgE in‑vitro allergy testing measures allergen‑specific IgE antibodies in serum and serves as an alternative to skin testing when skin tests are contraindicated or impractical.
    When indicatedIndicated when SPT is unsafe or not useful (eg, extensive dermatitis, dermatographism, patient on skin‑suppressive therapy), or when clinical circumstances favor blood testing.
    Coverage and limitsPolicy covers sIgE testing when allergens are selected based on individual history/exam/environment, with up to 20 allergen‑specific tests per year; note that same‑day in‑vitro sIgE testing performed with SPT does not meet coverage criteria.